1. Inicio
  2. Publicaciones
  3. Real-world effectiveness and safety of bimekizumab for hidradenitis suppurativa: An ambispective observational study

Real-world effectiveness and safety of bimekizumab for hidradenitis suppurativa: An ambispective observational study

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Pons-Benavent, M
  • Fernandez-Crehuet, P
  • Vilarrasa, E
  • Albanell-Fernandez, C
  • Morales-Tedone, E
  • Rausell-Felix, F
  • Alcala-Garcia, R
  • Matellanes-Palacios, M
  • Martin-Ezquerra, G
  • Alfageme, F
  • Ciudad-Blanco, C
  • Lopez-Villaescusa, MT
  • Garbayo-Salmons, P
  • Martorell, A
  • Cuenca-Barrales, C
  • Molina-Leyva, A

Grupos

Abstract

In this original research, we present the results in terms of effectiveness and safety of bimekizumab for hidradenitis suppurativa in real clinical practice. Results indicated significant improvement in all activity scores and patient-reported outcomes at week 16, including a notable decrease in mean IHS4 from 27.1 to 15.6 (p < 0.001), HS-PGA from 5.1 to 3.2 (p < 0.001), VAS pain from 8.3 to 4.7 (p < 0.001) and DLQI from 21.6 to 12.6 (p < 0.001). Bimekizumab, administered every 2 or 4 weeks, was well-tolerated with no discontinuations and no new safety concerns identified. These findings corroborate the drug's effectiveness and favourable safety profile observed in phase 3 clinical trials, supporting its use in real-world clinical practice for treating HS.

Datos de la publicación

ISSN/ISSNe:
0004-8380, 1440-0960

AUSTRALASIAN JOURNAL OF DERMATOLOGY  WILEY

Tipo:
Article
Páginas:
198-202
PubMed:
38895808
Factor de Impacto:
0,639 SCImago ℠
Cuartil:
Q2 SCImago ℠

Citas Recibidas en Web of Science: 13

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • bimekizumab; biologic therapy; effectiveness; hidradenitis suppurativa; safety

Compartir